 |
Case Report
Lacrimal gland extranodal marginal zone B-cell lymphoma (EMZL) with high-grade transformation: A case report
1 William Carey College of Osteopathic Medicine, 498 Tuscan Ave, Hattiesburg, MS, USA
2 University of Alabama School of Optometry, Central Plant #1, 1716 University Blvd, Birmingham, AL, USA
Address correspondence to:
Kenzie Hendrix
13484 Windsong Dr, Gulfport, MS 39503,
USA
Message to Corresponding Author
Article ID: 100102Z10KH2022
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Hendrix K, Patel S, Ayers R. Lacrimal gland extranodal marginal zone B-cell lymphoma (EMZL) with high-grade transformation: A case report. J Case Rep Images Oncology 2022;8:100102Z10KH2022.ABSTRACT
Introduction: Non-Hodgkin’s lymphoma (NHL) comprises a diverse collection of hematologic malignancies that is commonly prevalent worldwide. Although the survival rate of NHL has improved with early detection, treatment, and preventative measures; NHLs can still present within various locations involving the lymphatic system.
Case Report: We present a case of a 57-year-old white female patient who presented to an optometry clinic with complaints of left lacrimal gland swelling and gradual ptosis for six months. The patient refused referral, diagnosis, and treatment of the lymphoma for the subsequent year. After further testing, extranodal marginal zone B-cell lymphoma (EMZL) of the lacrimal gland associated with rare high-grade transformation was found. A robust chemotherapeutic regimen was utilized and successfully led to remission. Lacrimal gland lymphomas are typically lower-grade and have shown a good prognosis with treatment as seen in this case.
Conclusion: The challenges presented with treatment refusal increased the likelihood of high-grade transformation over time. Detection and treatment options for patients diagnosed with lacrimal NHL should emphasize on collaborative efforts from different aspects of patient care.
Keywords: Extranodal marginal zone B-cell lymphoma, Lacrimal gland lymphoma, Ocular adnexal lymphoma, Ocular malignancy
SUPPORTING INFORMATION
Acknowledgments
We would like to thank Dr. Ayers for her time and efforts on the management of this paper and entrusting the use of a patient’s medical history to expound on uncharted territory for further medical application, knowledge, and improvement.
Author ContributionsKenzie Hendrix - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Sunny Patel - Substantial contributions to conception and design, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Rhonda Ayers - Acquisition of data, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2022 Kenzie Hendrix et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
